07/05/2017

The FDA approved a new formulation of EMEND.

Merck has received FDA approval for a new formulation of EMEND for injection that has a lower concentration of edetate disodium (EDTA), an inactive ingredient.  This new formulation (5.4 mg EDTA, NDC 0006-3061-00) will replace the existing formulation (18.8 mg EDTA, NDC 0006-3941-32).  The purpose of this formulation change is to support ongoing regulatory activities for EMEND. 

Please ensure that your systems and processes are updated with the new NDC.

Before prescribing EMEND^® (fosaprepitant dimeglumine) for injection, please read the accompanying Prescribing Information (5.4 mg EDTA formulation). The Patient Information also is available.